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Abstract 
Over the last two decades epidermal growth factor receptor (EGFR) kinase has become an 
important target to treat non-small cell lung cancer (NSCLC). Currently, three generations of 
EGFR kinase-targeted small molecule drugs have been FDA approved. They nominally produce a 
response at the start of treatment and lead to a substantial survival benefit for patients. However, 
long-term treatment results in acquired drug resistance and further vulnerability to NSCLC. 
Therefore, novel EGFR kinase inhibitors that specially overcome acquired mutations are urgently 
needed. To this end, we carried out a comprehensive study of different EGFR kinase mutants using 
a structural systems pharmacology strategy. Our analysis shows that both wild-type and mutated 
structures exhibit multiple conformational states that have not been observed in solved crystal 
structures. We show that this conformational flexibility accommodates diverse types of ligands 
with multiple types of binding modes. These results provide insights for designing a new-
generation of EGFR kinase inhibitor that combats acquired drug-resistant mutations through a 
multi-conformation-based drug design strategy.  
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Introduction 
Epidermal growth factor receptor (EGFR) is one of four members of the transmembrane 
epidermal growth factor receptor family (EGF/ErbB receptor family). It is typically activated by 
an epidermal growth factor (EGF) that binds to the extracellular domain which protrudes from the 
cell membrane thereby regulating signaling pathways1. Mutation of the EGFR kinase domain leads 
to higher activity thereby stimulating four major downstream signaling pathways including 
MAPK/ERK, PLCg/PKC, JAK/STAT and PI3K/AKT which impact transcription and cell cycle 
progression2 leading to cancers and inflammatory diseases3. Specifically, it has been shown that 
diverse mutations in the EGFR kinase domain, typically L858R and del746-750, are associated 
with non-small cell lung cancer (NSCLC) which accounts for about 80% to 85% of all lung cancer 
cases4. Thus, EGFR kinase inhibitors that target these activation mutations are desirable for the 
treatment of NSCLC. Since 2009, five EGFR kinase inhibitors have been approved by the US 
Food and Drug Administration (FDA). The first two, Gefitinib and Erlotinib, show efficacy at the 
start of treatment. However, after about 12 months, drug resistance from an acquired T790M 
mutation arises5. Thus, a second-generation EGFR kinase inhibitor, Afatinib, was developed for 
the T790M mutation. Because of the limited therapeutic potential of Afatinib6, soon after, a third-
generation of EGFR kinase inhibitors, Osimertinib and Olmutinib, were developed. Afatinib, 
Osimertinib and Olmutinib are all irreversible inhibitors7 that form a covalent bond with Cys797. 
However, the occurrence of an acquired C797S mutation greatly reduces the efficacy of these three 
covalent drugs. Therefore, to date, this acquired resistance remains a major challenge in the 
treatment of NSCLC8-9. New EGFR kinase inhibitors that overcome these acquired mutations are 
needed. Recently, Jia et al. discovered an allosteric EGFR kinase inhibitor (EAI045)10, which 
overcomes both T790M and C797S mutations, and offers a means for treating NSCLC. Further, a 
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few non-covalent ATP-competitive inhibitors that bind to the ATP binding site were rationally 
designed to overcome acquired resistance11-15. For example, Marcel Günther et al.14 developed a 
reversible inhibitor that can inhibit the L858R/T790M/C797S triple mutant. Hwangseo Park et 
al.15 also identified a few ATP-competitive inhibitors that overcome the Del746-
750/T790M/C797S/ triple mutant. This next-generation allosteric or non-covalent inhibitors 
demonstrate promising potential and an opportunity to overcome the multiple mutations through 
designing elaborate inhibitors that match the mutated binding site of the EGFR kinase16. These 
findings prompted us to revisit the EGFR kinase binding site to obtain a detailed understanding of 
the similarity and differences between the wild-type and mutant EGFR kinases.  
Currently, with many available EGFR structures, there is the data-driven opportunity to focus 
on the EGFR binding site using a structural systems pharmacology strategy17-20. We collected all 
released structures of the EGFR kinase domain to analyze the overall conformational space of the 
binding sites as well as the respective kinase-ligand binding modes. We focused on all diverse 
acquired mutations at the binding sites, exploring the binding site flexibility of EGFR kinase 
domains with the del746-750/T790M/C797S/ mutation and the L858R/T790M/C797S mutations 
by using µs-scale molecular dynamics (MD). MD simulation has been successfully applied to 
study the EGFR conformation space at a computational physiological environment21-24. For 
example, Park et. al explored the EGFR conformational transition between the inactive and active 
state to determine the role of gatekeeper mutation on inhibitor selectivity using MD simulations21. 
Kannan et. al used the combined MD simulation with binding assay data to reveal a mutant specific 
pocket24. Additionally, we scrutinized the binding site features at an atomic level using the 
function-site interaction fingerprint approach and the volumetric analysis of surface properties. 
Our analyses show both wild-type and mutated structures encompass multiple conformational 
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states. Novel conformational state that have not been observed in the solved structures can exist. 
The conformational flexibility in the structure accommodates diverse types of ligands with 
multiple types of binding modes.  These results provide us with critical insights into future drug 
design in treating drug resistant NSCLC and other cancers25. 
Results 
1. EGFR kinase conformations and mutations 
The similarities and differences in EGFR kinase binding sites can be determined by comparing 
their X-ray structures. We clustered EGFR kinase structures in our dataset into two kinase states, 
active and inactive and into six classes (Figure 1a). In these classes, the side chain of the aspartic 
acid in the DFG motif points in three different directions: “DFG-In”, “DFG-Out”, and DFG-!"In. 
In DFG-!"In, the side chain of the aspartic acid points to the roof26. Similarly, the C-helix also 
exhibits significant displacements called “In” and “Out”, and the state between them (labeled 
“!"Out”). The number of x-ray structures and the representative structure in each class are shown 
in Figure 1a (a complete clustering of structures is in Table S1). Using the representative structure 
from each class, the major differences in the P-loop, C-helix and DFG motifs are highlighted in 
Figure 1b. In the active state (Class-1 and Class-2), the DFG motif is in a “DFG-In” state.  The C-
helix is found in the “In” state (class-1, Figure 1a-b) or has a small displacement referred to as 
“!"Out” (Class-2, Figure 1a-b). In the inactive kinase (class-3-6), the DFG motif is found in three 
directions and the C-helix is found in the “Out” state in all structures. These distinctly different 
conformations in the binding site of EGFR kinases facilitates the identification of potential sites 
outside of the conserved ATP-binding site, providing a structural basis to accelerate structure-
based drug design through the discovery of novel binding modes. 
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Acquired multi-drug resistance motivates the search for drugs that can target mutated structures. 
To begin this process, we catalog the currently available conformations of EGFR kinase domains, 
both wildtype and mutations, according to the scheme described above (Figure 1c). The wildtype 
(WT) EGFR kinases (37 structures) fall into four classes of conformation (Class-1,3,4,5). The 
L858R/T790 mutation (41structures) also exhibits different conformational states (Class-1,2,3,5,6). 
Other mutated classes such as T790M, which have a limited number of released structures (14 
structures), present fewer unique conformations (Class-1,2,3). As catalogued, the WT and mutated 
structures can have the same conformation. For example, three types of EGFR kinase, the WT, 
L858R and T790M/L858R (Figure 1c) all adopt the Class-5 conformation. In summary, WT and 
mutated structures both present multiple conformations. From a drug design perspective, the good 
news is that multiple conformations suggest flexibility in the EFGR kinase domain providing 
opportunities to design potent and specific inhibitors by accommodating a unique conformation. 
The bad news is the challenge to protein-ligand docking and modeling quantitative structure-
activity relationship since the ligand-induced conformation is not known a priori. Here we attempt 
to address this shortcoming. 
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Figure 1. EGFR kinase structure dataset with mutations. (a) Classes of EGFR kinase domain    
conformations. (b) Comparison of different classes of EGFR kinase with representative 
conformations. (c) Network of currently released structure conformations and mutations. 
 
    We also marked two important motifs, the R- and C-spine27-29 (Figure S1). The catalytic C-spine 
is assumed highly stable since it is strikingly similar in all six classes of EGFR states. However, 
the R-spine has different architectures. In Class-1 and 2 at the active state, the R-spine residues are 
linearly connected. In Class-3 and 4 at the DFG-in/C-helix-out inactive state, the R-spine is 
partially assembled because the C-helix displacement leads to M766 movement. In the DFG-out 
inactive state (Class-5 and 6), the R-spine is not assembled because the sidechain of the F856 
residue flips to the other side of the DFG peptide.    
 
2. Comparing binding sites among EGFR wildtype and mutants 
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We calculate changes in the size and shape of the binding pockets for different classes of 
conformation.  The volume of the binding pockets is 1119 Å3, 953 Å3, 950 Å3, 1056 Å3 and 972 
Å3 for Class-1 to 5, respectively (Figure S2). These pockets are not significantly different, however, 
the volume of the binding pocket in Class-6 is significantly increased (1913 Å3). It can thus 
accommodate more diverse types of small molecule ligands. The difference in the shape and size 
of the binding pockets is shown in Figure 2. Given that the Class-1 conformation (Figure 2a) is the 
most frequently observed (Figure 1a), we compared the binding cavities of the other five classes 
with that of Class-1. Specifically, we decomposed the binding cavity into five sub-pockets: front 
pocket (FP),  GxGxxG motif at the P-loop (G-rich-loop), and back clefts BP-I, BP-II, and BP-III30, 
and quantitatively compared them (Figure 2b-f (upper and lower). BP-I is located at the back cleft 
close to the adenine pocket; BP-II includes the hydrophobic pocket at the back cleft; BP-III is the 
sub-pocket at the back cleft comprising the DFG peptide, C-terminal end of the C-helix and the 
N-terminus of the catalytic loop. Table S2 lists the volume of every sub-pocket.  
Firstly, compared with the back cleft of Class-1, the volume of the back cleft in Class-2 and 
Class-5 is smaller. Their back binding sub-pocket is not formed (Figure 2b and 2e). However, the 
BP-II cleft of Class-3, the BP-II cleft of Class-4 and the BP-II, III clefts of Class-6 is present 
(Figure 2c,2d and 2f). It is worth noting that the C-helix in Class 2-6 is in “OUT” or “ !"Out” state. 
Thus, the C-helix displacement does not always induce the formation of the back cleft. Secondly, 
in Class 1-6, the volumetric size of the FP region that binds ATP is similar but the shape is slightly 
different (Figure 2 and Table S2). Finally, for the sub-pocket at the G-rich loop, a large binding 
pocket is formed in Class-2, Class-5 and Class-6. However, there is no space to accommodate a 
ligand in Class-3 and Class-4 similar to Class-1 (Figure 2b-f). Interestingly, Class-6 (Figure 2f) is 
different from other classes; besides the regions of FP and G-rich-loop, a large sub-pocket is 
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formed at BP-II and BP-III. Thus, the cavity of Class-6 has adequate space, not only at the ATP-
competitive site, but also at the allosteric site. This conformational mode may provide the 
structural basis for the design of diverse type-II and/or type-III EGFR kinase inhibitors31-32.  
 
Figure 2. Differences in binding pockets. The cavity of Class-1 is showed in cyan and the cavity 
of each other class in blue, respectively. (a) The Class-1 binding pocket shown in PDB 1m17 as a 
reference showing every region. (b-f) Significant pairwise differences (upper); quantitative 
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difference of every pairwise binding pocket illustrated using a radar chart and a contour interval 
of 100 Å3 (lower). 
In summary, we compared the different binding pockets quantitatively and qualitatively. The 
changes in the conformations in the C-helix and DFG motif induces diverse sub-pockets within 
the binding cavities. It is worth noting that we only analyze the difference in the binding cavities 
using the rigid x-ray structures. Nevertheless, the induced sub-pockets present the diverse shape 
and size of the binding pockets. It suggests that the plasticity of the EGFR kinase binding pocket 
combined with the inducing dynamic conformational space introduced by molecular dynamics has 
great potential for designing inhibitors with desired selectivity profiles.  
3. Dynamic conformational space of the binding sites 
Starting from their X-ray structures, the µs-scale equilibration of the trajectories yields a large 
number of conformations for the wildtype and different mutated EGFR kinases. The trajectory 
analysis provides information on the similarity of conformations and frequent conformational 
transitions based on the total energy curves (Figure S3), the root mean square deviation of 
Ca atoms (Ca-RMSD) (Figure S4) and the root mean square fluctuation of Ca  atoms (Ca-RMSF) 
(Figure S5). The main collective motions, as inferred from the first principal component of PCA, 
are shown in Figure S6. For all three systems, their ATP binding pockets show little variation. 
Around the binding site, the flexibility mainly comes from P-loop, the activation loop and C-helix. 
From specific detailed comparison of the binding sites, these conformations show a high degree 
of deviation from the initial crystal x-ray structure (PDB id: 1m17, Class-1, Figure 1a). Starting 
from the DFG-In/C-helix-In conformations, the resulting equilibrated structures present different 
conformations including both the active and inactive states (Figure 3). Among them, the DFG 
motif exhibits significant displacement from DFG-In to DFG-out, and the C-helix transitions from 
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C-helix-in to C-helix-out. In the trajectory of wild-type structures (Figure 3a), all six classes of 
conformation can be sampled. As shown in Figure 3b-c for the mutated structures of del746-
750/T790M/C797S and L858R/T790M/C797S, the conformations range from active state (Class-
1 and Class-2) to inactive (Class-3 and Class-4). It is well known that conformational transition 
needs to overcome the free energy barrier33. It could be the reason that we cannot capture Class-5 
and Class-6 conformations using unbiased MD simulation given our current MD time-scale. To 
explore a larger conformational space improved sampling technologies or longer simulation time 
are required22-23 as described by Shan22, Sutto23, and Park21. Nevertheless, it is clear, even from 
traditional MD simulation, that multiple conformational states of the EGFR kinase in both WT and 
mutated systems exist. Importantly, we observe a new conformational state (labeled as Class-D1 
in Figure 3c), which doesn’t occur in the EGFR kinase structure dataset. This new conformation 
(Figure 4) has “DFG-!"In/C-helix-out”, in which the DFG flipping and C-helix-out displacement 
are similar to that of Class-4. The difference is that the salt bridge between K745 and E762 
occurred in Class-D1 and a hydrogen-bond interaction formed between D855 and K745. This salt 
bridge and the hydrogen-bond interaction stabilize this dynamic conformation (Figure 4). In the 
Class-D1 state, when C-helix displacement occurs, the sheets consisting of beta-strands 1-5 have 
a combined displacement outward (Figure 4). It will be interesting to screen for novel inhibitors 
using this new conformation.  
We further analyzed the features of the Class-D1 binding pocket. The volume of the binding 
pocket is 1204 Å3 (Figure S7), which is slightly larger than that of Class 1-5. We compared the 
Class-D1 binding site with the other six classes of binding sites. The main difference between 
Class-D1 and Class 1-5 is the BP-III region. The main difference from Class 6 is the G-rich-loop 
region (Figure S8). Obviously, the Class-D1 binding pocket has a large sub-pocket at the BP-III 
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region. More specifically, we calculated the similarity between the Class-D1 binding pocket and 
the other six classes of binding pockets using the volumetric distance34 (Table S3), which shows 
the Class-6 binding site is most similar to Class-D1. Like Class 6, the slightly larger BP-III sub-
pocket is also available in the Class-D1 state. Additionally, to estimate the possible binding mode, 
we screened the whole kinase structurome, including 3180 kinase-ligand structures35, to obtain the 
most similar binding pocket to the Class-D1 binding pocket.  The top complex (Table S4) is a 
JAK1 kinase structure36 (pdb id: 4e4n), where the ligand (0NL) binds to the pocket by bearing a 
heterocycloamine scaffold, forming hydrogen bonds with the hinge peptide and a t-butyl 
carbamate at the G-rich-loop region (Figure S9). We also noted that the distance between the t-
butyl and the C-helix is 9.6 Å, which means this BP-III sub-pocket region is not fully utilized. This 
binding mode for the JAK1-0NL complex can guide new EGFR inhibitor design through binding 
the Class-D1 conformation. The complete structure file (PDB format) of this new conformation is 
available as Supporting Information.  
 
Figure 3. Scatter density plot of the distributions of conformation space for the different systems 
(a) wildtype, (b) del746-750/T790M/C797S and (c) L858R/T790M/C797S. The y axis represents 
the distance of K745 Nz : E762 Cd and the x axis represents the flexibility of the DFG peptide. d2-
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d1=d2[C797 Ca : D855 Cg]-d1[C797 Ca : F856 Cz]. High-density and low-density regions are 
colored in red and blue, respectively. 
 
Figure 4. The Class-D1 of conformation (cyan color) comparing with that of Class-4 in purple 
color.  
 
In summary, the MD simulation reveals more conformational states than those in the released 
x-ray structure dataset. It is important to analyze the multiple conformational states in the context 
of the diverse inhibitors that bind to those different conformations. Stated another way, multiple 
conformations will facilitate novel inhibitor design with a specific SAR. Note, however, that the 
ligand could also induce a new EGFR kinase conformation with a yet to be discovered binding 
pocket37 which points to the need for further structure determination  of new ligand-bound complex 
structures, as well as further computational studies to sample a larger conformation space in the 
process of drug design in order to obtain the desired SAR38.  
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4. EGFR kinase-ligand binding characterization 
 
Figure 5. Interaction details between the amino acids that constitute the binding site and the 
corresponding ligand. (a) the contact frequency of each amino acid providing the binding 
interaction and the corresponding locations. (b) distribution of interacting amino acids in the 3D 
binding site (purple) and the top 5 residues with the highest contact times (green). 
 
It is well known that the kinase ATP binding site is highly conserved across the whole kinome.  
In order to achieve the desired selectivity, it is critical to understand the atomic details of kinase-
inhibitor interactions35. Here, using all released EGFR kinase crystal structures, we analyze and 
characterize the atomic details of interactions between the ligand and the residues that constitute 
the EGFR kinase ATP binding site (see Methods and Table S5 for specific PDB structures). Figure 
5 shows the contact frequency between specific residues and the bound ligand. Seven types of 
interatomic interaction are defined based on geometric rules 39 but not energy (see Methods). The 
analysis identifies 39 amino acids that are close to the binding site (Figure 5a). The 39 residues are 
located predominantly in beta-sheets or helixes as shown in Figure 5a and 5b. The residues with 
  15 
the top 5 contact frequencies are L718, V726, A743, M793 and L844. They are located at b1-3, 
Hinge and b6 (Figure 5b in green) and form a core binding pocket. The core binding pocket is 
highly hydrophobic, largely conserved and consistent with previous results35. The core binding 
pocket accommodates the adenine base of ATP or the ATP-competitive inhibitor. The high contact 
frequencies at the core binding pocket also suggests that most of the co-crystallized EGFR kinase 
inhibitors are ATP-competitive. However, by selectively binding other residues with lower contact 
frequency, higher selectivity can be anticipated.  
To reveal the nature of binding specificity, we compare the pairwise similarity of aligned 
residue-ligand functional site interaction fingerprints (Fs-IFPs) (see Methods). Hierarchical 
clustering of the Fs-IFPs for all EGFR kinase-ligand co-crystallized structures was conducted and 
the binding modes grouped into six clusters that represent different binding modes (Figure 6a and 
Table S6). In cluster-1 (Figure 6b), the ligand is located at the position of the ATP binding site, 
where the core binding pocket is highlighted as aforementioned. It is not surprising that most 
inhibitors fall into this cluster. Typically, there are two or three hydrogen-bond interactions 
between the ligand and the amino acids located at the hinge31. Since the core binding pocket is 
conserved, this type of inhibitor has a multi-targeted effect across the kinome. For example, the 
ligand STO (1,2,3,4-tetrahydrogen staurosporine) ( Figure 6b) is a derivative of the  
natural product staurosporine40, which is known to have broad cross-reactivity41. Following the 
cross reactivity observed, the ligand STO has a specific kinase spectrum that can be targeted. By 
combining the target spectrum of a given compound, further SAR optimization becomes a valid 
strategy26, 42. By using this strategy, a close analogue of staurosporine (PKC-412, a multi-kinase 
inhibitor) was approved in April 2017 for treating acute myeloid leukemia (AML), 
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myelodysplastic syndrome (MDS) and advanced systemic mastocytosis43-45. Similar to cluster-1, 
the cluster-2 interaction patterns also include the ATP-competitive binding mode (Figure 6c).  
However, in this cluster the kinase is in the inactive state and belongs to the Class-6 conformation 
as described in Figure 1. In this case the ligand does not have any interaction with the C-helix. 
Rather the benzenesulfonyl fluoride ligand fragment presents characteristic interactions, namely 
the aromatic p-p stacking interaction with the phenylalanine side chain of the DFG motif and the 
electrostatic interactions with the amino acids on the G-rich loop. In cluster-3 (Figure 6d), the 
ligand also presents an ATP-competitive binding mode. However, different from cluster-1, the 
ligand has a hydrophobic fragment penetrating deeply into the hydrophobic pocket that adjoins the 
core binding pocket and is located at the back of the kinase binding site30. The hydrophobic pocket 
is often used to achieve the desired selectivity, but mutation of the gatekeeper residues directly 
affects the efficacy of this type of inhibitor46. Cluster-4 (Figure 6e) has a non-ATP-competitive 
binding mode. The ligand is located at the back of the binding site, and occupies the hydrophobic 
pocket, similar to cluster-3, as well as the allosteric site47. In this cluster, the C-helix is displaced 
outward to the “Out” state and opens up the allosteric site. Thus, the ligand forms interactions with 
the DFG motif and the C-helix. The allosteric binding mode provides high selectivity overcoming 
the T790M/C797S mutations10. In cluster-5 (Figure 6f), ligand binding presents two features. 
Firstly, the ligand has a phenyl group to bind the hydrophobic pocket that is similar to cluster-3 
and cluster-4. Secondly, the tail of the ligand interacts with not only the sidechain of aspartic acid 
from the DFG motif but also the sidechain of asparagine 842 at b6. It is notable that the position 
of the tail is similar to that in cluster-2, but the binding mode is totally different. Firstly, the tail of 
the ligand forms an interaction with the aspartic acid of DFG-in in cluster-5, but with the 
phenylalanine of DFG-out in cluster-2. Secondly, the tail extends towards the A-loop and forms 
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an interaction with Asn842 in cluster-5, but extends towards the P-loop and is in contact with the 
G-rich loop in cluster-2. In cluster-6, the ligand is an ATP-competitive binder. The furan group of 
the ligand not only forms very subtle interactions with the hydrophobic pocket but also forms polar 
interactions with K745, E762 and the DGF motif. As aforementioned, in cluster-4, the C-helix 
contributes to the binding affinity of the allosteric inhibitor. However, although the inhibitors in 
cluster-6 are not allosteric inhibitors, the C-helix is in the "C-helix-In" state in close proximity to 
the oxygen atoms of the furan group thereby forming polar interactions. Thus, the furan group 
provides unique binding characteristics. 
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Figure 6. EGRF ligand-binding clusters and features. (a) hierarchical cluster analysis. The number 
represents the index of every structure (Table S5). (b-g) the clustered binding modes (clusters 1-
6) are shown using the PDB structures 2itu, 5u8l, 4hjo, 5d41, 4jq8 and 4jeb, respectively. The 
dash-line circles (orange) highlight the binding characteristics of the core binding pocket in: (b) 
the location of binding G-rich loop and DFG motif; (c) the hydrophobic pocket; (d) the 
hydrophobic pocket and the allosteric site; (e) the hydrophobic pocket and the location of binding 
DFG and Asn842; (f) and the combined binding position with the interactions from the 
hydrophobic pocket and the allosteric site (g). 
 
In summary, the binding modes of co-crystallized EGFR kinase-ligand complexes are diverse. 
They provide the structural basis for mediating inhibitor selectivity, important to keep in mind 
when designing mutant-sensitive inhibitors.  
 
Conclusions 
We have explored the impact of mutations on structural conformation of the EGFR kinase 
domain for all released crystal x-ray structures. From a detailed structural analysis, we identified 
six classes of conformation which focus on the flipping of the DFG motif and the displacement of 
the C-helix. There is no apparent correlation between these mutations and conformation. For 
example, the common T790M mutation adopted not only the typical DFG-in/C-helix-in 
conformation but also the DFG-out/C-helix-out. We suggest that the conformations of the EGFR 
kinase are flexible and can fall into distinct locally stable states. From the perspective of drug 
design, multi-conformation-based drug screening should be of significant value when targeting 
EGFR kinases. 
We also explored the dynamic conformation space occupied by the EGFR kinase using µs-
level MD simulation. We not only sampled the multiple different conformations from Class-1 to 
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Class-6 but also found a new conformation mode. In the two acquired mutated kinase systems, we 
did not sample Class-5 and Class-6 conformations; advanced sampling technologies are needed. 
Less of an issue perhaps since Class-5 and Class-6 conformations that were obtained from the 
released ligand-bound structures (Figure 1b), as well as taking conformational flexibility into 
account, suggests that the EGFR kinase-ligand binding would induce a specific binding mode and 
EGFR kinase conformation change. Recently, Sonti et al.38 reported a similar ligand-induced 
binding mechanism for Abelson tyrosine kinase (Abl). Abl belongs to the TK group, like the EGFR 
kinase, and has 60% sequence similarity48. Therefore, it is important for EGFR kinase-ligand SAR 
to take the induced binding mechanism into consideration. This presents a challenge to in silico 
compound screening for it requires the protein target be considered not as a static structure but as 
an ensemble of conformations49.  
Such a change in conformation often results in a change in the binding site. We found that the 
outward displacement of the C-helix does not always form the BP sub-pockets, (Figure 2b and 2e). 
Moreover, with these conformational changes the volume and shape of the binding cavities shows 
systematic plasticity (Figure 2b-f), which can be further elucidated into distinctive binding patterns 
through binding diverse inhibitors. The derived Fs-IFPs highlight this distinctive protein-ligand 
binding patterns at the atomic level. It is our hope that within each sub-cluster of fingerprints, the 
unique binding modes will provide useful clues in designing unique molecular fragments for a new 
series of EGFR kinase inhibitors.  
 
Method 
1. Dataset of EGFR kinase structures 
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We collected all 127 PDB structures of the EGFR kinase domain released through Dec. 2017 
from the Protein Data Bank ( www.rcsb.org )50 by using the human EGFR UniProt51 identifier, 
P00533. There are 20 apo and 107 holo PDB structures in the dataset. The binding sites of all 
structures were aligned using the SMAP software52-54. We clustered all structures based on the Ca-
RMSD of the EGFR N-terminal lobes. The mutations closest to the binding site of each structure 
was extracted to determine the relationships between the conformation patterns and the mutations. 
2. Differentiating the binding sites 
    To differentiate the different binding sites, first the given binding sites were pairwise aligned 
using the SMAP tool54. Then, each binding site and each sub-pocket was detected using the Surflex 
software55-56 with default proto parameters. For each sub-pocket, a set of residues bordering the 
sub-pocket were chose based on Liao’s description30. Then the volumetric size and shape of each 
binding site or each sub-pocket was inferred using the volumetric analysis of surface properties 
(VASP) software34, in which all computations were carried out at 0.5 A resolution. Lastly, 
differentiating the binding sites was determined using the volumetric difference of constructive 
solid geometry34. The similarity was calculated by using the volumetric distance 𝑣(%,'), 
𝑣(%,') = 1 − 𝑣(𝑥 ∩ 𝑦)min	(𝑣 𝑥 , 𝑣(𝑦)) 
where, 𝑣(𝑖)  represents the volume of a given binding site 𝑖  in Å3. 𝑣(𝑥 ∩ 𝑦)  represents the 
volumetric intersection of 𝑣(𝑥) and 𝑣(𝑦) for x and y are binding pockets. 
3. Sampling the conformational space using MD 
    We carried out microsecond-level molecular dynamics (MD) simulation for three systems, the 
wild-type and two acquired mutated types (L858R/T790M/C797S and del746-
750/T790M/C719S). First, the initial structure was prepared from PDB 1m17 with the DFG-in/C-
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helix-in active conformation as the wild-type EGFR kinase domain. Then the corresponding 
mutated models were built for each system, respectively, using PDB 1m17 as the template and the 
software modeller57. Then each structure was solvated in a cubic box of water molecules with 12Å 
distance from the solvated molecules and neutralized by adding Cl- and Na+ using an ACEMD 
setup script58. Finally, a general short-MD protocol was used for initial minimization and 
equilibration including 2ps minimization, 100ps for NVT, 1ns for NPT with heavy-atom 
constraints and 1ns for NPT without any constraints. The next stage was a 1.5 µs equilibration 
process without the constraint and the last 1000ns of MD trajectories were retained for further 
analysis.  
The MD simulations were carried out using the ACEMD software58 with the CharMM27 force 
field for protein and the TIP3P water model for the water molecule59. The electrostatic interaction 
was treated using PME and SHAKE constraints were applied with a 4fs integration time step60. 
The temperature was kept at 300K using a Langevin bath method and the pressure was maintained 
at 1 ATM using the Berendsen method. The trajectories were analyzed using the MMTSB toolset61. 
For the reaction coordinate (RC) of scatter density distribution, we used the salt-bridge distance 
between K745 and E762 as one RC. Because the flexibility of Cys797 is low as shown in Figure 
S4, we measured the two distances from C797 to D855 and F856, where the difference constitutes 
another RC. 
4. Function-site interaction fingerprint encoding 
Function-site interaction fingerprints (Fs-IFP) are an efficient means to determine functional 
site binding characteristics and to compare binding sites on a proteome scale as detailed in previous 
applications35, 62-63. In brief, the Fs-IFP method includes three steps. Step 1 prepares the dataset. 
In this paper, we collected all EGFR kinase-ligand structures as our dataset. Step 2 aligns all 
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function sites. Here we used the SMAP software52-54 with default parameters. Thus, we obtained 
all aligned residues within the binding pocket. Step 3 encodes the binding site–ligand interaction. 
Based on the aligned residues, we confirmed that every binding site could be described using 39 
amino acids that comprised the binding pocket. Then the interactions between every amino acid 
and the corresponding ligand were encoded using a 7-bit array that represents 7 types of 
interactions: ((1)van der Waals; (2) aromatic face to face; (3) aromatic edge to face; (4) hydrogen 
bond (protein as hydrogen bond donor); (5) hydrogen bond (protein as hydrogen bond acceptor); 
(6) electrostatic interaction (protein positively charged); and (7) electrostatic interaction)39. Finally, 
the kinase–ligand interactions of each complex structure were encoded using a length of 273 bits 
(7 bits × 39 residues). The encoding was done using IChem software64. Further, the similarity of 
the pairwise Fs-IFPs was calculated using the Tanimoto coefficient (TC). Based on all-against-all 
pairwise TC similarity, the hierarchical cluster analysis was carried out using R with the single 
linkage method65. 
 
Supporting information 
    Figure S1-9 illustrate the C- and R-spine analysis, the volume and shape of the binding pockets, 
the analysis of different MD trajectories, PCA, the Class-D1 binding pocket, the different between 
the Class-D1 binding site and all the other six classes of EGFR binding sites, and the screened top 
complex. Table S1-6 describes the EGFR kinase structure dataset, the volume of every sub-pocket 
conformation, the similarity list, the top similar complex, the index and the pdb id of every kinase 
structure, and the classes of the binding mode, respectively. The Class-D1 EGFR kinase structure 
(PDB). 
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